Markets:

Overview

News

Currencies

International

Treasuries

Bristol-Myers Squibb (NY:BMY)

58.48 +1.17 (+2.05%)

Streaming Delayed Price Updated: 11:15 AM EDT, May 19, 2026 Add to My Watchlist

Quote

Overview Detailed Quote Charting Historical Prices

News

All News News Headlines Press Releases

Research

Quarterly Reports Insider Filings Other Filings

All News about Bristol-Myers Squibb

< Previous 1 2

...

5 6 7 8 9 10 11 12 13

...

89 90 Next >

Bristol-Myers Squibb (BMY) Stock Trades Up, Here Is Why

October 30, 2025

Shares of biopharmaceutical company Bristol Myers Squibb (NYSE:BMY) jumped 4.3% in the morning session after the company posted third-quarter financial results that beat expectations and raised its...

Via StockStory

Topics Artificial Intelligence Earnings

Bristol Myers' New Treatments Drive Q3 Beat — And The Company's Raising Its Outlook ↗

October 30, 2025

Bristol Myers beats Q3 forecasts with $12.22 billion revenue and a higher 2025 sales outlook, driven by strong demand for Reblozyl, Camzyos, and Breyanzi.

Via Benzinga

10 Health Care Stocks Whale Activity In Today's Session ↗

October 30, 2025

Via Benzinga

Earnings Scheduled For October 30, 2025 ↗

October 30, 2025

Via Benzinga

Bristol Myers Squibb To Acquire Orbital Therapeutics In $1.5B Deal ↗

October 10, 2025

Via Stocktwits

Meta Tumbles 10%, Google Marks Historic Rally: What's Moving Markets Thursday? ↗

October 30, 2025

Wall Street saw a cautious tone on Thursday as major tech-heavy indexes edged lower, weighed down by mixed earnings from the mega-caps and the lingering impact of hawkish remarks from Fed Chair Jerome...

Via Benzinga

Topics Economy

BMY CEO Expects Cancer Drug Opdivo To Drive Strong Sales In 2025 ↗

October 30, 2025

Via Stocktwits

Bristol-Myers Squibb (NYSE:BMY) Reports Bullish Q3

October 30, 2025

Biopharmaceutical company Bristol Myers Squibb (NYSE:BMY) reported revenue ahead of Wall Streets expectations in Q3 CY2025, with sales up 2.8% year on year to $12.22 billion. The company’s full-year...

Via StockStory

Bristol Myers Squibb Co (NYSE:BMY) Q3 2025 Earnings Beat Estimates ↗

October 30, 2025

Bristol Myers Squibb Q3 2025 earnings beat estimates with $1.63 EPS and $12.22B revenue, driven by strong new product sales.

Via Chartmill

Topics Earnings

Bristol Myers Squibb Reports Third Quarter Financial Results for 2025

October 30, 2025

From Bristol Myers Squibb

Via Business Wire

What to Expect from Bristol-Myers Squibb's Earnings ↗

October 29, 2025

Via Benzinga

Bristol-Myers Squibb (BMY) To Report Earnings Tomorrow: Here Is What To Expect

October 28, 2025

Biopharmaceutical company Bristol Myers Squibb (NYSE:BMY) will be reporting results this Thursday morning. Here’s what you need to know.

Via StockStory

Topics Artificial Intelligence

3 Dividend-Paying Drug Stocks to Buy at a Discount ↗

October 27, 2025

Some of the largest drugmakers in the world are trading at attractive valuations. Are they worth buying?

Via The Motley Fool

Topics Intellectual Property

Bristol Myers Squibb Presents Two Late-Breaking Presentations Demonstrating Sotyktu (deucravacitinib) Efficacy in Psoriatic Arthritis and Systemic Lupus Erythematosus

October 27, 2025

From Bristol Myers Squibb

Via Business Wire

Avidity Shareholders Win Big As Novartis Moves Fast On $12 Billion Deal ↗

October 27, 2025

Avidity Biosciences (NASDAQ: RNA) shares soar as Novartis (NYSE: NVS) agrees to acquire them for $12 billion in cash.

Via Benzinga

Bristol Myers Squibb Presents Encouraging Data from Phase 1 Breakfree-1 Study of CD19 NEX-T™ CAR T Cell Therapy in Three Chronic Autoimmune Diseases at ACR Convergence 2025

October 25, 2025

From Bristol Myers Squibb

Via Business Wire

Inhibrx Stock Soars on Breakthrough Chondrosarcoma Trial Results: A New Dawn for Rare Cancer Treatment

October 24, 2025

San Diego, CA – October 24, 2025 – Inhibrx (NASDAQ: INBX) shares have surged dramatically, skyrocketing over 70% in pre-market and after-hours trading, following the announcement of overwhelmingly...

Via MarketMinute

Checking In on The Trade Desk, Bristol Myers Squibb, and Other Stocks ↗

October 22, 2025

Motley Fool analysts Karl Thiel, Rick Munarriz, and Tim Beyers offer up three stocks that face dark clouds they can see through.

Via The Motley Fool

Topics Workforce

Nurix Therapeutics (NASDAQ: NRIX) Stock Soars as Pivotal Phase 2 Study for Bexobrutideg Ignites Investor Confidence

October 22, 2025

San Francisco, CA – October 22, 2025 – Nurix Therapeutics (NASDAQ: NRIX) has captured significant market attention, with its stock experiencing a notable surge following the announcement of the...

Via MarketMinute

Why Replimune Stock Was Soaring Today ↗

October 20, 2025

An investigational treatment, used in combination with another cancer medication, took an important step forward after several setbacks.

Via The Motley Fool

2 High-Yield Dividend Stocks Too Cheap to Ignore ↗

October 19, 2025

They are both yielding above 5%.

Via The Motley Fool

Topics Intellectual Property World Trade

3 S&P 500 Stocks We Find Risky

October 17, 2025

The S&P 500 (^GSPC) is home to the biggest and most well-known companies in the market, making it a go-to index for investors seeking stability. But not all large-cap stocks are created equal - some...

Via StockStory

Topics Stocks

This Drug Discovery Stock Is Leading the Charge In Bringing AI to Healthcare. But Is It a Buy? ↗

October 16, 2025

All of the top 20 drugmakers have a subscription with this software business.

Via The Motley Fool

Topics Artificial Intelligence

Wall Street's Most Accurate Analysts Spotlight On 3 Health Care Stocks With Over 3% Dividend Yields ↗

October 15, 2025

Via Benzinga

Bristol Myers Squibb to Present Data at ESMO® 2025 Showcasing Progress of Oncology Portfolio Across Diverse Tumor Types

October 13, 2025

From Bristol Myers Squibb

Via Business Wire

Branded Pharmaceuticals Stocks Q2 Earnings Review: Supernus Pharmaceuticals (NASDAQ:SUPN) Shines

October 12, 2025

As the Q2 earnings season comes to a close, it’s time to take stock of this quarter’s best and worst performers in the branded pharmaceuticals industry, including Supernus Pharmaceuticals (NASDAQ:SUPN)...

Via StockStory

Topics Artificial Intelligence Intellectual Property

Bristol Myers Expands Cell Therapy Portfolio With Orbital Therapeutics Acquisition ↗

October 10, 2025

Bristol Myers Squibb is acquiring Orbital Therapeutics for $1.5 billion, expanding its RNA and in vivo CAR T-cell therapy portfolio.

Via Benzinga

Bristol Myers Squibb Strengthens and Diversifies Cell Therapy Portfolio with Acquisition of Orbital Therapeutics

October 10, 2025

From Bristol Myers Squibb

Via Business Wire

Bristol Myers Squibb and TV Host Gail Simmons Tackle Stigma in Schizophrenia with New Initiative Spotlighting the Power of Support and Connection

October 10, 2025

From Bristol Myers Squibb

Via Business Wire

3 Value Stocks with Warning Signs

October 09, 2025

Value stocks typically trade at discounts to the broader market, offering patient investors the opportunity to buy businesses when they’re out of favor. The key risk, however, is that these stocks are...

Via StockStory

< Previous 1 2

...

5 6 7 8 9 10 11 12 13

...

89 90 Next >

Stock Quote API & Stock News API supplied by www.cloudquote.io
Quotes delayed at least 20 minutes.
By accessing this page, you agree to the Privacy Policy and Terms Of Service.

Bristol-Myers Squibb (NY:BMY)

All News about Bristol-Myers Squibb

Starting at $3.75/week.

Subscribe Today